Ligand Pharmaceuticals (LGND) Other financing activities (2012 - 2026)

Ligand Pharmaceuticals (LGND) has 15 years of Other financing activities data on file, last reported at $7.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities rose 81.29% year-over-year to $7.7 million; the trailing twelve-month figure through Mar 2026 stood at $226000.0 (up 102.04% YoY), and the FY2025 full-year result was $47.5 million, changed N/A from the prior year.
• Other financing activities grew to $7.7 million in Q1 2026, from -$19.9 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $21.4 million in Q3 2024 to a low of -$46.3 million in Q4 2024.
• A 5-year average of $216125.0 and a median of $3.4 million in 2023 frame the typical range for Other financing activities.
• Peak annual rise in Other financing activities reached 22680.0% in 2023, while the deepest fall reached 586.32% in 2023.
• Tracing LGND's Other financing activities over 5 years: stood at $3.3 million in 2022, then plunged by 586.32% to -$15.9 million in 2023, then slumped by 190.48% to -$46.3 million in 2024, then surged by 57.0% to -$19.9 million in 2025, then surged by 138.48% to $7.7 million in 2026.
• Business Quant data shows LGND's Other financing activities at $7.7 million in Q1 2026, -$19.9 million in Q4 2025, and $8.2 million in Q2 2025.